nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—HSP90AA1—oviduct—uterine cancer	0.0424	0.131	CbGeAlD
Nedocromil—FPR1—renal system—uterine cancer	0.0272	0.0841	CbGeAlD
Nedocromil—HSP90AA1—exocrine gland—uterine cancer	0.0245	0.0756	CbGeAlD
Nedocromil—CYSLTR2—female reproductive system—uterine cancer	0.0242	0.0748	CbGeAlD
Nedocromil—PTGDR—vagina—uterine cancer	0.0186	0.0575	CbGeAlD
Nedocromil—HSP90AA1—myometrium—uterine cancer	0.0136	0.0419	CbGeAlD
Nedocromil—PTGDR—lymph node—uterine cancer	0.012	0.0372	CbGeAlD
Nedocromil—Disorder sight—Progesterone—uterine cancer	0.012	0.0427	CcSEcCtD
Nedocromil—CYSLTR1—smooth muscle tissue—uterine cancer	0.0118	0.0365	CbGeAlD
Nedocromil—Disorder sight—Medroxyprogesterone Acetate—uterine cancer	0.0108	0.0387	CcSEcCtD
Nedocromil—HSP90AA1—epithelium—uterine cancer	0.0106	0.0329	CbGeAlD
Nedocromil—CYSLTR1—mammalian vulva—uterine cancer	0.0106	0.0329	CbGeAlD
Nedocromil—HSP90AA1—uterine cervix—uterine cancer	0.0106	0.0326	CbGeAlD
Nedocromil—HSP90AA1—smooth muscle tissue—uterine cancer	0.0103	0.0317	CbGeAlD
Nedocromil—CYSLTR1—uterus—uterine cancer	0.0101	0.0313	CbGeAlD
Nedocromil—HSP90AA1—decidua—uterine cancer	0.0101	0.0311	CbGeAlD
Nedocromil—HSP90AA1—renal system—uterine cancer	0.00987	0.0305	CbGeAlD
Nedocromil—HSP90AA1—endometrium—uterine cancer	0.00954	0.0295	CbGeAlD
Nedocromil—HSP90AA1—mammalian vulva—uterine cancer	0.00923	0.0285	CbGeAlD
Nedocromil—CYSLTR1—female reproductive system—uterine cancer	0.00911	0.0282	CbGeAlD
Nedocromil—HSP90AA1—uterus—uterine cancer	0.0088	0.0272	CbGeAlD
Nedocromil—CYSLTR1—vagina—uterine cancer	0.00824	0.0255	CbGeAlD
Nedocromil—HSP90AA1—female reproductive system—uterine cancer	0.00791	0.0244	CbGeAlD
Nedocromil—HSP90AA1—female gonad—uterine cancer	0.00719	0.0222	CbGeAlD
Nedocromil—HSP90AA1—vagina—uterine cancer	0.00715	0.0221	CbGeAlD
Nedocromil—Viral infection—Progesterone—uterine cancer	0.00631	0.0225	CcSEcCtD
Nedocromil—Dysphonia—Medroxyprogesterone Acetate—uterine cancer	0.00628	0.0224	CcSEcCtD
Nedocromil—CYSLTR1—lymph node—uterine cancer	0.00533	0.0165	CbGeAlD
Nedocromil—Ear pain—Progesterone—uterine cancer	0.00485	0.0173	CcSEcCtD
Nedocromil—Gastroenteritis—Progesterone—uterine cancer	0.00467	0.0167	CcSEcCtD
Nedocromil—HSP90AA1—lymph node—uterine cancer	0.00463	0.0143	CbGeAlD
Nedocromil—Nasal congestion—Progesterone—uterine cancer	0.00454	0.0162	CcSEcCtD
Nedocromil—Arthritis—Progesterone—uterine cancer	0.00426	0.0152	CcSEcCtD
Nedocromil—Bronchitis—Progesterone—uterine cancer	0.00344	0.0123	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Progesterone—uterine cancer	0.00332	0.0119	CcSEcCtD
Nedocromil—Pain—Carboplatin—uterine cancer	0.00331	0.0118	CcSEcCtD
Nedocromil—Influenza—Medroxyprogesterone Acetate—uterine cancer	0.00324	0.0116	CcSEcCtD
Nedocromil—Pneumonia—Progesterone—uterine cancer	0.00321	0.0115	CcSEcCtD
Nedocromil—Bronchitis—Medroxyprogesterone Acetate—uterine cancer	0.00312	0.0111	CcSEcCtD
Nedocromil—Conjunctivitis—Progesterone—uterine cancer	0.0031	0.0111	CcSEcCtD
Nedocromil—Body temperature increased—Carboplatin—uterine cancer	0.00306	0.0109	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Medroxyprogesterone Acetate—uterine cancer	0.00301	0.0108	CcSEcCtD
Nedocromil—Sinusitis—Progesterone—uterine cancer	0.00299	0.0107	CcSEcCtD
Nedocromil—Rhinitis—Progesterone—uterine cancer	0.00287	0.0102	CcSEcCtD
Nedocromil—Pharyngitis—Progesterone—uterine cancer	0.00284	0.0101	CcSEcCtD
Nedocromil—Visual impairment—Progesterone—uterine cancer	0.00276	0.00985	CcSEcCtD
Nedocromil—Sinusitis—Medroxyprogesterone Acetate—uterine cancer	0.00271	0.00968	CcSEcCtD
Nedocromil—Pharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.00257	0.00919	CcSEcCtD
Nedocromil—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.0025	0.00892	CcSEcCtD
Nedocromil—Tremor—Progesterone—uterine cancer	0.00233	0.00833	CcSEcCtD
Nedocromil—Pneumonia—Dactinomycin—uterine cancer	0.00227	0.00809	CcSEcCtD
Nedocromil—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.00221	0.00789	CcSEcCtD
Nedocromil—Cough—Progesterone—uterine cancer	0.00217	0.00776	CcSEcCtD
Nedocromil—Rash erythematous—Epirubicin—uterine cancer	0.00213	0.00762	CcSEcCtD
Nedocromil—Chest pain—Progesterone—uterine cancer	0.00212	0.00757	CcSEcCtD
Nedocromil—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.00212	0.00755	CcSEcCtD
Nedocromil—Otitis media—Epirubicin—uterine cancer	0.0021	0.0075	CcSEcCtD
Nedocromil—Feeling hot—Epirubicin—uterine cancer	0.00208	0.00743	CcSEcCtD
Nedocromil—Dry mouth—Progesterone—uterine cancer	0.00207	0.00741	CcSEcCtD
Nedocromil—Anaphylactic shock—Progesterone—uterine cancer	0.00203	0.00726	CcSEcCtD
Nedocromil—Stinging—Epirubicin—uterine cancer	0.00202	0.0072	CcSEcCtD
Nedocromil—Pharyngitis—Dactinomycin—uterine cancer	0.00201	0.00717	CcSEcCtD
Nedocromil—Dysphonia—Epirubicin—uterine cancer	0.00199	0.00709	CcSEcCtD
Nedocromil—Rash erythematous—Doxorubicin—uterine cancer	0.00197	0.00705	CcSEcCtD
Nedocromil—Otitis media—Doxorubicin—uterine cancer	0.00194	0.00694	CcSEcCtD
Nedocromil—Feeling hot—Doxorubicin—uterine cancer	0.00193	0.00688	CcSEcCtD
Nedocromil—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.00192	0.00686	CcSEcCtD
Nedocromil—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00188	0.00671	CcSEcCtD
Nedocromil—Stinging—Doxorubicin—uterine cancer	0.00187	0.00666	CcSEcCtD
Nedocromil—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00184	0.00658	CcSEcCtD
Nedocromil—Dysphonia—Doxorubicin—uterine cancer	0.00184	0.00656	CcSEcCtD
Nedocromil—Dyspnoea—Progesterone—uterine cancer	0.00181	0.00647	CcSEcCtD
Nedocromil—Viral infection—Epirubicin—uterine cancer	0.00181	0.00646	CcSEcCtD
Nedocromil—Dyspepsia—Progesterone—uterine cancer	0.00179	0.00639	CcSEcCtD
Nedocromil—Cough increased—Epirubicin—uterine cancer	0.00179	0.00637	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Progesterone—uterine cancer	0.00176	0.00627	CcSEcCtD
Nedocromil—Fatigue—Progesterone—uterine cancer	0.00175	0.00626	CcSEcCtD
Nedocromil—Pain—Progesterone—uterine cancer	0.00174	0.00621	CcSEcCtD
Nedocromil—Viral infection—Doxorubicin—uterine cancer	0.00167	0.00598	CcSEcCtD
Nedocromil—Gastrointestinal pain—Progesterone—uterine cancer	0.00166	0.00594	CcSEcCtD
Nedocromil—Cough increased—Doxorubicin—uterine cancer	0.00165	0.0059	CcSEcCtD
Nedocromil—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00164	0.00587	CcSEcCtD
Nedocromil—Pneumonia—Etoposide—uterine cancer	0.00164	0.00586	CcSEcCtD
Nedocromil—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.00579	CcSEcCtD
Nedocromil—Urticaria—Progesterone—uterine cancer	0.00162	0.00577	CcSEcCtD
Nedocromil—Abdominal pain—Progesterone—uterine cancer	0.00161	0.00574	CcSEcCtD
Nedocromil—Body temperature increased—Progesterone—uterine cancer	0.00161	0.00574	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00159	0.00568	CcSEcCtD
Nedocromil—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00159	0.00567	CcSEcCtD
Nedocromil—Leukopenia—Dactinomycin—uterine cancer	0.00158	0.00563	CcSEcCtD
Nedocromil—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00151	0.00538	CcSEcCtD
Nedocromil—Hypersensitivity—Progesterone—uterine cancer	0.0015	0.00535	CcSEcCtD
Nedocromil—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.00523	CcSEcCtD
Nedocromil—Asthenia—Progesterone—uterine cancer	0.00146	0.00521	CcSEcCtD
Nedocromil—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.0052	CcSEcCtD
Nedocromil—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.0052	CcSEcCtD
Nedocromil—Diarrhoea—Progesterone—uterine cancer	0.00139	0.00497	CcSEcCtD
Nedocromil—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00136	0.00485	CcSEcCtD
Nedocromil—Dizziness—Progesterone—uterine cancer	0.00134	0.0048	CcSEcCtD
Nedocromil—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00472	CcSEcCtD
Nedocromil—Eczema—Epirubicin—uterine cancer	0.00132	0.00471	CcSEcCtD
Nedocromil—Vomiting—Progesterone—uterine cancer	0.00129	0.00462	CcSEcCtD
Nedocromil—Rash—Progesterone—uterine cancer	0.00128	0.00458	CcSEcCtD
Nedocromil—Dermatitis—Progesterone—uterine cancer	0.00128	0.00457	CcSEcCtD
Nedocromil—Headache—Progesterone—uterine cancer	0.00127	0.00455	CcSEcCtD
Nedocromil—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00126	0.0045	CcSEcCtD
Nedocromil—Dysgeusia—Etoposide—uterine cancer	0.00125	0.00446	CcSEcCtD
Nedocromil—Fatigue—Dactinomycin—uterine cancer	0.00124	0.00442	CcSEcCtD
Nedocromil—Pain—Dactinomycin—uterine cancer	0.00123	0.00439	CcSEcCtD
Nedocromil—Eczema—Doxorubicin—uterine cancer	0.00122	0.00436	CcSEcCtD
Nedocromil—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00122	0.00435	CcSEcCtD
Nedocromil—Nausea—Progesterone—uterine cancer	0.00121	0.00431	CcSEcCtD
Nedocromil—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00118	0.0042	CcSEcCtD
Nedocromil—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00418	CcSEcCtD
Nedocromil—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.00415	CcSEcCtD
Nedocromil—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.00414	CcSEcCtD
Nedocromil—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00115	0.00412	CcSEcCtD
Nedocromil—Leukopenia—Etoposide—uterine cancer	0.00114	0.00407	CcSEcCtD
Nedocromil—Abdominal pain—Dactinomycin—uterine cancer	0.00114	0.00406	CcSEcCtD
Nedocromil—Body temperature increased—Dactinomycin—uterine cancer	0.00114	0.00406	CcSEcCtD
Nedocromil—Cough—Etoposide—uterine cancer	0.00111	0.00397	CcSEcCtD
Nedocromil—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00109	0.00391	CcSEcCtD
Nedocromil—Chest pain—Etoposide—uterine cancer	0.00109	0.00387	CcSEcCtD
Nedocromil—Hypersensitivity—Dactinomycin—uterine cancer	0.00106	0.00378	CcSEcCtD
Nedocromil—Anaphylactic shock—Etoposide—uterine cancer	0.00104	0.00371	CcSEcCtD
Nedocromil—Asthenia—Dactinomycin—uterine cancer	0.00103	0.00368	CcSEcCtD
Nedocromil—Influenza—Epirubicin—uterine cancer	0.00103	0.00366	CcSEcCtD
Nedocromil—Eosinophilia—Epirubicin—uterine cancer	0.00102	0.00362	CcSEcCtD
Nedocromil—Bronchitis—Epirubicin—uterine cancer	0.000986	0.00352	CcSEcCtD
Nedocromil—Diarrhoea—Dactinomycin—uterine cancer	0.000983	0.00351	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000953	0.0034	CcSEcCtD
Nedocromil—Influenza—Doxorubicin—uterine cancer	0.000949	0.00339	CcSEcCtD
Nedocromil—Eosinophilia—Doxorubicin—uterine cancer	0.000939	0.00335	CcSEcCtD
Nedocromil—Dyspnoea—Etoposide—uterine cancer	0.000927	0.00331	CcSEcCtD
Nedocromil—Pneumonia—Epirubicin—uterine cancer	0.00092	0.00328	CcSEcCtD
Nedocromil—Vomiting—Dactinomycin—uterine cancer	0.000914	0.00326	CcSEcCtD
Nedocromil—Bronchitis—Doxorubicin—uterine cancer	0.000913	0.00326	CcSEcCtD
Nedocromil—Rash—Dactinomycin—uterine cancer	0.000906	0.00324	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Etoposide—uterine cancer	0.000898	0.00321	CcSEcCtD
Nedocromil—Fatigue—Etoposide—uterine cancer	0.000897	0.0032	CcSEcCtD
Nedocromil—Pain—Etoposide—uterine cancer	0.00089	0.00318	CcSEcCtD
Nedocromil—Conjunctivitis—Epirubicin—uterine cancer	0.000889	0.00317	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000882	0.00315	CcSEcCtD
Nedocromil—Sinusitis—Epirubicin—uterine cancer	0.000858	0.00306	CcSEcCtD
Nedocromil—Nausea—Dactinomycin—uterine cancer	0.000854	0.00305	CcSEcCtD
Nedocromil—Pneumonia—Doxorubicin—uterine cancer	0.000851	0.00304	CcSEcCtD
Nedocromil—Gastrointestinal pain—Etoposide—uterine cancer	0.000851	0.00304	CcSEcCtD
Nedocromil—Urticaria—Etoposide—uterine cancer	0.000826	0.00295	CcSEcCtD
Nedocromil—Rhinitis—Epirubicin—uterine cancer	0.000823	0.00294	CcSEcCtD
Nedocromil—Abdominal pain—Etoposide—uterine cancer	0.000822	0.00294	CcSEcCtD
Nedocromil—Body temperature increased—Etoposide—uterine cancer	0.000822	0.00294	CcSEcCtD
Nedocromil—Conjunctivitis—Doxorubicin—uterine cancer	0.000822	0.00294	CcSEcCtD
Nedocromil—Pharyngitis—Epirubicin—uterine cancer	0.000815	0.00291	CcSEcCtD
Nedocromil—Sinusitis—Doxorubicin—uterine cancer	0.000794	0.00283	CcSEcCtD
Nedocromil—Visual impairment—Epirubicin—uterine cancer	0.000791	0.00282	CcSEcCtD
Nedocromil—Hypersensitivity—Etoposide—uterine cancer	0.000766	0.00274	CcSEcCtD
Nedocromil—Rhinitis—Doxorubicin—uterine cancer	0.000761	0.00272	CcSEcCtD
Nedocromil—Pharyngitis—Doxorubicin—uterine cancer	0.000754	0.00269	CcSEcCtD
Nedocromil—Asthenia—Etoposide—uterine cancer	0.000746	0.00266	CcSEcCtD
Nedocromil—Visual impairment—Doxorubicin—uterine cancer	0.000732	0.00261	CcSEcCtD
Nedocromil—Diarrhoea—Etoposide—uterine cancer	0.000712	0.00254	CcSEcCtD
Nedocromil—Dysgeusia—Epirubicin—uterine cancer	0.0007	0.0025	CcSEcCtD
Nedocromil—Dizziness—Etoposide—uterine cancer	0.000688	0.00246	CcSEcCtD
Nedocromil—Vomiting—Etoposide—uterine cancer	0.000661	0.00236	CcSEcCtD
Nedocromil—Rash—Etoposide—uterine cancer	0.000656	0.00234	CcSEcCtD
Nedocromil—Dermatitis—Etoposide—uterine cancer	0.000655	0.00234	CcSEcCtD
Nedocromil—Headache—Etoposide—uterine cancer	0.000652	0.00233	CcSEcCtD
Nedocromil—Dysgeusia—Doxorubicin—uterine cancer	0.000647	0.00231	CcSEcCtD
Nedocromil—Leukopenia—Epirubicin—uterine cancer	0.00064	0.00228	CcSEcCtD
Nedocromil—Cough—Epirubicin—uterine cancer	0.000624	0.00223	CcSEcCtD
Nedocromil—Nausea—Etoposide—uterine cancer	0.000618	0.00221	CcSEcCtD
Nedocromil—Chest pain—Epirubicin—uterine cancer	0.000608	0.00217	CcSEcCtD
Nedocromil—Dry mouth—Epirubicin—uterine cancer	0.000595	0.00212	CcSEcCtD
Nedocromil—Leukopenia—Doxorubicin—uterine cancer	0.000592	0.00211	CcSEcCtD
Nedocromil—Anaphylactic shock—Epirubicin—uterine cancer	0.000583	0.00208	CcSEcCtD
Nedocromil—Cough—Doxorubicin—uterine cancer	0.000577	0.00206	CcSEcCtD
Nedocromil—Chest pain—Doxorubicin—uterine cancer	0.000563	0.00201	CcSEcCtD
Nedocromil—Dry mouth—Doxorubicin—uterine cancer	0.00055	0.00197	CcSEcCtD
Nedocromil—Anaphylactic shock—Doxorubicin—uterine cancer	0.00054	0.00193	CcSEcCtD
Nedocromil—Dyspnoea—Epirubicin—uterine cancer	0.00052	0.00186	CcSEcCtD
Nedocromil—Dyspepsia—Epirubicin—uterine cancer	0.000513	0.00183	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000503	0.0018	CcSEcCtD
Nedocromil—Fatigue—Epirubicin—uterine cancer	0.000503	0.00179	CcSEcCtD
Nedocromil—Pain—Epirubicin—uterine cancer	0.000499	0.00178	CcSEcCtD
Nedocromil—Dyspnoea—Doxorubicin—uterine cancer	0.000481	0.00172	CcSEcCtD
Nedocromil—Gastrointestinal pain—Epirubicin—uterine cancer	0.000477	0.0017	CcSEcCtD
Nedocromil—Dyspepsia—Doxorubicin—uterine cancer	0.000475	0.0017	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000466	0.00166	CcSEcCtD
Nedocromil—Fatigue—Doxorubicin—uterine cancer	0.000465	0.00166	CcSEcCtD
Nedocromil—Urticaria—Epirubicin—uterine cancer	0.000463	0.00165	CcSEcCtD
Nedocromil—Pain—Doxorubicin—uterine cancer	0.000461	0.00165	CcSEcCtD
Nedocromil—Abdominal pain—Epirubicin—uterine cancer	0.000461	0.00165	CcSEcCtD
Nedocromil—Body temperature increased—Epirubicin—uterine cancer	0.000461	0.00165	CcSEcCtD
Nedocromil—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000441	0.00158	CcSEcCtD
Nedocromil—Hypersensitivity—Epirubicin—uterine cancer	0.00043	0.00153	CcSEcCtD
Nedocromil—Urticaria—Doxorubicin—uterine cancer	0.000429	0.00153	CcSEcCtD
Nedocromil—Abdominal pain—Doxorubicin—uterine cancer	0.000427	0.00152	CcSEcCtD
Nedocromil—Body temperature increased—Doxorubicin—uterine cancer	0.000427	0.00152	CcSEcCtD
Nedocromil—Asthenia—Epirubicin—uterine cancer	0.000418	0.00149	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—YWHAE—uterine cancer	0.000399	0.00101	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SOCS3—uterine cancer	0.000399	0.00101	CbGpPWpGaD
Nedocromil—Diarrhoea—Epirubicin—uterine cancer	0.000399	0.00142	CcSEcCtD
Nedocromil—Hypersensitivity—Doxorubicin—uterine cancer	0.000398	0.00142	CcSEcCtD
Nedocromil—HSP90AA1—Disease—AKR1C1—uterine cancer	0.000396	0.001	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CDKN2B—uterine cancer	0.000396	0.000999	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—KRAS—uterine cancer	0.00039	0.000984	CbGpPWpGaD
Nedocromil—Asthenia—Doxorubicin—uterine cancer	0.000387	0.00138	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by VEGF—AKT1—uterine cancer	0.000387	0.000977	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKR1C1—uterine cancer	0.000387	0.000976	CbGpPWpGaD
Nedocromil—Dizziness—Epirubicin—uterine cancer	0.000386	0.00138	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—IGF1R—uterine cancer	0.000384	0.00097	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—CXCL8—uterine cancer	0.000384	0.000969	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—FBXW7—uterine cancer	0.000383	0.000966	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—CXCL8—uterine cancer	0.000383	0.000965	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CDKN2B—uterine cancer	0.000382	0.000964	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—CDKN1B—uterine cancer	0.000375	0.000947	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IGF1R—uterine cancer	0.000371	0.000937	CbGpPWpGaD
Nedocromil—Vomiting—Epirubicin—uterine cancer	0.000371	0.00132	CcSEcCtD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	0.00037	0.000934	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—CXCL8—uterine cancer	0.000369	0.000932	CbGpPWpGaD
Nedocromil—Diarrhoea—Doxorubicin—uterine cancer	0.000369	0.00132	CcSEcCtD
Nedocromil—Rash—Epirubicin—uterine cancer	0.000368	0.00131	CcSEcCtD
Nedocromil—Dermatitis—Epirubicin—uterine cancer	0.000367	0.00131	CcSEcCtD
Nedocromil—Headache—Epirubicin—uterine cancer	0.000365	0.0013	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—SMAD3—uterine cancer	0.000361	0.000912	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—KRAS—uterine cancer	0.000359	0.000905	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—BIRC5—uterine cancer	0.000358	0.000904	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—PIK3CA—uterine cancer	0.000358	0.000904	CbGpPWpGaD
Nedocromil—Dizziness—Doxorubicin—uterine cancer	0.000357	0.00127	CcSEcCtD
Nedocromil—CYSLTR1—GPCR ligand binding—CXCL8—uterine cancer	0.000356	0.000897	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—POLD1—uterine cancer	0.000355	0.000895	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SMAD3—uterine cancer	0.000349	0.000881	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—CXCL8—uterine cancer	0.000347	0.000877	CbGpPWpGaD
Nedocromil—Nausea—Epirubicin—uterine cancer	0.000346	0.00124	CcSEcCtD
Nedocromil—HSP90AA1—Innate Immune System—FGFR2—uterine cancer	0.000345	0.000871	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—FGFR2—uterine cancer	0.000345	0.00087	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—ERBB2—uterine cancer	0.000344	0.000868	CbGpPWpGaD
Nedocromil—Vomiting—Doxorubicin—uterine cancer	0.000343	0.00122	CcSEcCtD
Nedocromil—HSP90AA1—Disease—DCN—uterine cancer	0.000343	0.000865	CbGpPWpGaD
Nedocromil—Rash—Doxorubicin—uterine cancer	0.00034	0.00121	CcSEcCtD
Nedocromil—Dermatitis—Doxorubicin—uterine cancer	0.00034	0.00121	CcSEcCtD
Nedocromil—Headache—Doxorubicin—uterine cancer	0.000338	0.00121	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—RNF43—uterine cancer	0.000337	0.00085	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MET—uterine cancer	0.000336	0.000847	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—CXCL8—uterine cancer	0.000336	0.000847	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—STK11—uterine cancer	0.000335	0.000844	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—CCL2—uterine cancer	0.000333	0.00084	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—FGFR2—uterine cancer	0.000333	0.00084	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKR1C1—uterine cancer	0.000332	0.000838	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—HRAS—uterine cancer	0.000332	0.000837	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—PIK3CA—uterine cancer	0.00033	0.000832	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—EP300—uterine cancer	0.000329	0.000831	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IRF1—uterine cancer	0.000329	0.000829	CbGpPWpGaD
Nedocromil—Nausea—Doxorubicin—uterine cancer	0.000321	0.00114	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—SOCS3—uterine cancer	0.000313	0.000791	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—VEGFA—uterine cancer	0.000312	0.000787	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—INHBA—uterine cancer	0.000308	0.000778	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKR1C3—uterine cancer	0.000305	0.00077	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—HRAS—uterine cancer	0.000305	0.000769	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN2B—uterine cancer	0.0003	0.000757	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKR1C3—uterine cancer	0.000298	0.000751	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HMGA1—uterine cancer	0.000297	0.00075	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—RRM2—uterine cancer	0.000296	0.000746	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—ESR1—uterine cancer	0.000295	0.000744	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—FBXW7—uterine cancer	0.000295	0.000743	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—AKT1—uterine cancer	0.000293	0.000739	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IGF1R—uterine cancer	0.000291	0.000735	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PGR—uterine cancer	0.00029	0.000732	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—CXCL8—uterine cancer	0.00029	0.000732	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—DCN—uterine cancer	0.000287	0.000725	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—ESR1—uterine cancer	0.000285	0.000719	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—NRAS—uterine cancer	0.000279	0.000703	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKR1C1—uterine cancer	0.000278	0.0007	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—YWHAE—uterine cancer	0.000277	0.000698	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SMAD3—uterine cancer	0.000274	0.000691	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—FBXW7—uterine cancer	0.000272	0.000686	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CYP11A1—uterine cancer	0.000271	0.000683	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—AKT1—uterine cancer	0.000269	0.000679	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—NRAS—uterine cancer	0.000269	0.000679	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CDKN2A—uterine cancer	0.000266	0.00067	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FBXW7—uterine cancer	0.000265	0.000669	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—VEGFA—uterine cancer	0.000265	0.000668	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—CXCL8—uterine cancer	0.000263	0.000664	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—NRAS—uterine cancer	0.000262	0.00066	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—FGFR2—uterine cancer	0.000261	0.000659	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CCL2—uterine cancer	0.00026	0.000655	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKR1C3—uterine cancer	0.000256	0.000645	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CCL2—uterine cancer	0.000251	0.000633	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—ERBB2—uterine cancer	0.000245	0.000619	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—PIK3CA—uterine cancer	0.000243	0.000612	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—SOCS3—uterine cancer	0.000241	0.000608	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—KRAS—uterine cancer	0.00024	0.000605	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CDKN2A—uterine cancer	0.000238	0.000599	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—TP53—uterine cancer	0.000236	0.000595	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CDKN1B—uterine cancer	0.000235	0.000594	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—PIK3CA—uterine cancer	0.000234	0.000591	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—STK11—uterine cancer	0.000232	0.000585	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—KRAS—uterine cancer	0.000232	0.000585	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—CCL2—uterine cancer	0.000231	0.000582	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—KRAS—uterine cancer	0.000225	0.000568	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—ESR1—uterine cancer	0.000223	0.000564	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—PIK3CA—uterine cancer	0.00022	0.000556	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SOCS3—uterine cancer	0.000217	0.000548	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—ERBB2—uterine cancer	0.000217	0.000547	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—ERBB2—uterine cancer	0.000216	0.000546	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—CTNNB1—uterine cancer	0.000215	0.000542	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKR1C3—uterine cancer	0.000214	0.000539	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN2B—uterine cancer	0.000213	0.000538	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—PIK3CA—uterine cancer	0.000213	0.000537	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—NRAS—uterine cancer	0.000211	0.000533	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CDKN1B—uterine cancer	0.00021	0.000531	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—ERBB2—uterine cancer	0.000209	0.000527	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PGR—uterine cancer	0.000208	0.000525	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN2B—uterine cancer	0.000208	0.000525	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—EP300—uterine cancer	0.000207	0.000521	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CXCL8—uterine cancer	0.000205	0.000518	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—HRAS—uterine cancer	0.000204	0.000515	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IGF1R—uterine cancer	0.000202	0.000509	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—FGFR2—uterine cancer	0.000201	0.000507	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—CXCL8—uterine cancer	0.000201	0.000507	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CDKN1B—uterine cancer	0.000201	0.000506	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CDKN1B—uterine cancer	0.0002	0.000506	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—EP300—uterine cancer	0.0002	0.000504	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—STK11—uterine cancer	0.000199	0.000502	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CYP19A1—uterine cancer	0.000199	0.000502	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—YWHAE—uterine cancer	0.000199	0.000501	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—AKT1—uterine cancer	0.000198	0.0005	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CXCL8—uterine cancer	0.000198	0.0005	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—HRAS—uterine cancer	0.000197	0.000497	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCL2—uterine cancer	0.000197	0.000496	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SMAD3—uterine cancer	0.000195	0.000491	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CDKN1B—uterine cancer	0.000194	0.000488	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—AKT1—uterine cancer	0.000191	0.000483	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—HRAS—uterine cancer	0.000191	0.000483	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FBXW7—uterine cancer	0.00019	0.000481	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SMAD3—uterine cancer	0.00019	0.000479	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CTNNB1—uterine cancer	0.00019	0.000478	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CTNNB1—uterine cancer	0.000189	0.000478	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—VEGFA—uterine cancer	0.000189	0.000477	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—NRAS—uterine cancer	0.000187	0.000471	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—FGFR2—uterine cancer	0.000186	0.000468	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PTEN—uterine cancer	0.000185	0.000466	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—EP300—uterine cancer	0.000185	0.000466	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PTEN—uterine cancer	0.000185	0.000466	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—PIK3CA—uterine cancer	0.000184	0.000464	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CTNNB1—uterine cancer	0.000183	0.000461	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—CXCL8—uterine cancer	0.000182	0.000461	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—KRAS—uterine cancer	0.000182	0.000459	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FGFR2—uterine cancer	0.000181	0.000457	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—AKT1—uterine cancer	0.00018	0.000454	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MTHFR—uterine cancer	0.000179	0.000451	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PTEN—uterine cancer	0.000178	0.00045	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EP300—uterine cancer	0.000176	0.000445	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EP300—uterine cancer	0.000176	0.000444	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—AKT1—uterine cancer	0.000174	0.000439	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EP300—uterine cancer	0.00017	0.000429	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—PIK3CA—uterine cancer	0.000167	0.000421	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—VEGFA—uterine cancer	0.000167	0.000421	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STK11—uterine cancer	0.000166	0.00042	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—NRAS—uterine cancer	0.000165	0.000416	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NRAS—uterine cancer	0.000165	0.000415	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—ERBB2—uterine cancer	0.000164	0.000414	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—VEGFA—uterine cancer	0.000161	0.000406	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—KRAS—uterine cancer	0.000161	0.000405	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NRAS—uterine cancer	0.000159	0.000401	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SOCS3—uterine cancer	0.000156	0.000393	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CXCL8—uterine cancer	0.000156	0.000392	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ESR1—uterine cancer	0.000155	0.000391	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HRAS—uterine cancer	0.000155	0.00039	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1B—uterine cancer	0.000152	0.000383	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—AKT1—uterine cancer	0.00015	0.000379	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDH1—uterine cancer	0.00015	0.000377	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—MTHFR—uterine cancer	0.00015	0.000377	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN2B—uterine cancer	0.000149	0.000377	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—NRAS—uterine cancer	0.000146	0.000369	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1R—uterine cancer	0.000145	0.000366	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CTNNB1—uterine cancer	0.000143	0.000362	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—uterine cancer	0.000142	0.000358	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—uterine cancer	0.000142	0.000358	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTEN—uterine cancer	0.00014	0.000353	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—uterine cancer	0.000137	0.000345	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—HRAS—uterine cancer	0.000137	0.000345	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—AKT1—uterine cancer	0.000136	0.000344	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCL2—uterine cancer	0.000136	0.000344	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SMAD3—uterine cancer	0.000136	0.000344	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EP300—uterine cancer	0.000133	0.000337	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—uterine cancer	0.000132	0.000334	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PIK3CA—uterine cancer	0.00013	0.000329	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PIK3CA—uterine cancer	0.00013	0.000329	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGFR2—uterine cancer	0.00013	0.000328	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PIK3CA—uterine cancer	0.000127	0.000322	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—uterine cancer	0.000126	0.000319	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ERBB2—uterine cancer	0.000126	0.000318	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—uterine cancer	0.000126	0.000318	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—uterine cancer	0.000126	0.000318	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3CA—uterine cancer	0.000126	0.000317	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NRAS—uterine cancer	0.000125	0.000315	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—uterine cancer	0.000122	0.000307	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HRAS—uterine cancer	0.000121	0.000304	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—AKT1—uterine cancer	0.000121	0.000304	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HRAS—uterine cancer	0.00012	0.000304	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1B—uterine cancer	0.000117	0.000295	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ERBB2—uterine cancer	0.000117	0.000294	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HRAS—uterine cancer	0.000116	0.000294	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CA—uterine cancer	0.000116	0.000292	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ERBB2—uterine cancer	0.000114	0.000287	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ESR1—uterine cancer	0.000111	0.000281	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CTNNB1—uterine cancer	0.00011	0.000279	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1B—uterine cancer	0.000108	0.000272	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CXCL8—uterine cancer	0.000108	0.000272	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PTEN—uterine cancer	0.000108	0.000272	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—uterine cancer	0.000107	0.000271	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HRAS—uterine cancer	0.000107	0.00027	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—AKT1—uterine cancer	0.000106	0.000269	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—AKT1—uterine cancer	0.000106	0.000268	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1B—uterine cancer	0.000105	0.000266	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—AKT1—uterine cancer	0.000104	0.000263	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—AKT1—uterine cancer	0.000103	0.000259	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EP300—uterine cancer	0.000103	0.000259	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CTNNB1—uterine cancer	0.000102	0.000257	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CTNNB1—uterine cancer	9.95e-05	0.000251	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTEN—uterine cancer	9.94e-05	0.000251	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CA—uterine cancer	9.87e-05	0.000249	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCL2—uterine cancer	9.79e-05	0.000247	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTEN—uterine cancer	9.69e-05	0.000245	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NRAS—uterine cancer	9.6e-05	0.000242	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—uterine cancer	9.54e-05	0.000241	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EP300—uterine cancer	9.48e-05	0.000239	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—AKT1—uterine cancer	9.46e-05	0.000239	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EP300—uterine cancer	9.24e-05	0.000233	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HRAS—uterine cancer	9.13e-05	0.00023	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NRAS—uterine cancer	8.86e-05	0.000224	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—uterine cancer	8.76e-05	0.000221	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NRAS—uterine cancer	8.65e-05	0.000218	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTEN—uterine cancer	8.32e-05	0.00021	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—uterine cancer	8.26e-05	0.000209	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB2—uterine cancer	8.16e-05	0.000206	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT1—uterine cancer	8.06e-05	0.000203	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—EP300—uterine cancer	7.94e-05	0.0002	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CXCL8—uterine cancer	7.74e-05	0.000195	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—uterine cancer	7.63e-05	0.000193	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CA—uterine cancer	7.59e-05	0.000192	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1B—uterine cancer	7.56e-05	0.000191	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—uterine cancer	7.44e-05	0.000188	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CTNNB1—uterine cancer	7.14e-05	0.00018	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HRAS—uterine cancer	7.02e-05	0.000177	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CA—uterine cancer	7.01e-05	0.000177	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTEN—uterine cancer	6.96e-05	0.000176	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CA—uterine cancer	6.84e-05	0.000173	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EP300—uterine cancer	6.64e-05	0.000167	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—uterine cancer	6.62e-05	0.000167	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HRAS—uterine cancer	6.49e-05	0.000164	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HRAS—uterine cancer	6.33e-05	0.00016	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—uterine cancer	6.28e-05	0.000159	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NRAS—uterine cancer	6.21e-05	0.000157	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT1—uterine cancer	6.2e-05	0.000157	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CA—uterine cancer	5.87e-05	0.000148	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT1—uterine cancer	5.73e-05	0.000145	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT1—uterine cancer	5.59e-05	0.000141	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—uterine cancer	5.34e-05	0.000135	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CA—uterine cancer	4.91e-05	0.000124	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKT1—uterine cancer	4.8e-05	0.000121	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—uterine cancer	4.75e-05	0.00012	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HRAS—uterine cancer	4.54e-05	0.000115	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT1—uterine cancer	4.01e-05	0.000101	CbGpPWpGaD
